Zeo ScientifiX, Inc. financial data

Symbol
ZEOX on OTC
Industry
Biological Products, (No Diagnostic Substances)
Location
3321 College Avenue, Suite 246, Davie, FL
State of incorporation
NV
Fiscal year end
October 31
Former names
Organicell Regenerative Medicine, Inc. (to 1/29/2024), Biotech Products Services & Research, Inc. (to 6/15/2018), BESPOKE TRICYCLES INC (to 9/14/2015)
Latest financial report
10-Q - Q2 2024 - Sep 16, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 47.7 % -32%
Quick Ratio 7.56 % +2.44%
Debt-to-equity -260 % -124%
Return On Assets -194 % +11.3%
Operating Margin -107 % +43.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.58M shares -99.5%
Common Stock, Shares, Outstanding 6.58M shares -99.6%
Entity Public Float 7.2M USD -39.8%
Common Stock, Value, Issued 6K USD -99.6%
Weighted Average Number of Shares Outstanding, Basic 6.26M shares -11.9%
Weighted Average Number of Shares Outstanding, Diluted 6.26M shares -11.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 4.8M USD +4.78%
Cost of Revenue 753K USD +17%
Research and Development Expense 93.7K USD -91.2%
General and Administrative Expense 9.17M USD -27.5%
Operating Income (Loss) -5.13M USD +41.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -9.49M USD -50.6%
Net Income (Loss) Attributable to Parent -4.54M USD +49.1%
Earnings Per Share, Basic -0.72 USD/shares +30.4%
Earnings Per Share, Diluted -0.72 USD/shares +30.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.42M USD +846%
Accounts Receivable, after Allowance for Credit Loss, Current 19K USD -8.49%
Inventory, Net 250K USD -2.93%
Assets, Current 1.73M USD +60%
Property, Plant and Equipment, Net 496K USD -58.7%
Assets 2.22M USD -9.56%
Employee-related Liabilities, Current 667K USD +0.03%
Liabilities, Current 3.63M USD +9.59%
Operating Lease, Liability, Noncurrent 28.6K USD -79.6%
Liabilities 3.64M USD +4.78%
Retained Earnings (Accumulated Deficit) -61M USD -8.05%
Stockholders' Equity Attributable to Parent -1.42M USD -39.1%
Liabilities and Equity 2.22M USD -9.56%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -575K USD +55.2%
Net Cash Provided by (Used in) Financing Activities -9K USD +99.1%
Net Cash Provided by (Used in) Investing Activities -16K USD +89.7%
Common Stock, Shares Authorized 2.5B shares 0%
Common Stock, Shares, Issued 6.58M shares -99.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.11M USD +74.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 22K USD +94.6%
Deferred Tax Assets, Valuation Allowance 5.56M USD +42.6%
Deferred Tax Assets, Gross 5.87M USD +39.7%
Operating Lease, Liability 82.4K USD -67.6%
Depreciation 73.4K USD -37%
Payments to Acquire Property, Plant, and Equipment 16K USD -89.7%
Lessee, Operating Lease, Liability, to be Paid 266K USD -0.51%
Property, Plant and Equipment, Gross 770K USD -63.1%
Operating Lease, Liability, Current 49.8K USD -58%
Lessee, Operating Lease, Liability, to be Paid, Year Two 28.9K USD -74.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 238K USD +89.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.59K USD
Preferred Stock, Shares Authorized 10M shares 0%
Operating Lease, Payments 5.48K USD 0%
Additional Paid in Capital 59.5M USD +10.4%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 19K USD -87.8%
Share-based Payment Arrangement, Expense 23K USD +1800%
Interest Expense 159K USD -61.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%